KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Share-based Compensation: 2020-2025

Historic Share-based Compensation for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Sep 2025 value amounting to $25.2 million.

  • Recursion Pharmaceuticals' Share-based Compensation rose 38.30% to $25.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $118.2 million, marking a year-over-year increase of 76.51%. This contributed to the annual value of $81.7 million for FY2024, which is 52.68% up from last year.
  • Recursion Pharmaceuticals' Share-based Compensation amounted to $25.2 million in Q3 2025, which was down 3.50% from $26.2 million recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Share-based Compensation ranged from a high of $36.1 million in Q1 2025 and a low of $1.8 million during Q1 2021.
  • Over the past 3 years, Recursion Pharmaceuticals' median Share-based Compensation value was $16.8 million (recorded in 2023), while the average stood at $20.2 million.
  • Data for Recursion Pharmaceuticals' Share-based Compensation shows a peak YoY spiked of 591.42% (in 2021) over the last 5 years.
  • Recursion Pharmaceuticals' Share-based Compensation (Quarterly) stood at $4.3 million in 2021, then skyrocketed by 77.26% to $7.7 million in 2022, then soared by 109.04% to $16.1 million in 2023, then soared by 91.37% to $30.8 million in 2024, then spiked by 38.30% to $25.2 million in 2025.
  • Its last three reported values are $25.2 million in Q3 2025, $26.2 million for Q2 2025, and $36.1 million during Q1 2025.